Selected article for: "monoclonal antibody and target monoclonal antibody"

Author: Liu, Justin K.H.
Title: The history of monoclonal antibody development – Progress, remaining challenges and future innovations
  • Document date: 2014_9_11
  • ID: 1e4dzy64_1
    Snippet: From the time the first monoclonal antibody was generated in 1975 and the first monoclonal antibody fully licenced in 1986, the field of monoclonal antibody development represents a novel way in which to target specific mutations and defects in protein structure and expression in a wide range of diseases and conditions. Today, with major rapid advancements in genetic sequencing and the translation of basic medical sciences research into clinical .....
    Document: From the time the first monoclonal antibody was generated in 1975 and the first monoclonal antibody fully licenced in 1986, the field of monoclonal antibody development represents a novel way in which to target specific mutations and defects in protein structure and expression in a wide range of diseases and conditions. Today, with major rapid advancements in genetic sequencing and the translation of basic medical sciences research into clinical practice, humanised monoclonal antibodies are now the fastest growing group of biotechnology-derived molecules in clinical trials currently [1] . The global value of the antibody market is approximately $20 billion per year [2] . About 30 monoclonal antibodies are currently approved by the FDA for use in humans for treating various diseases and conditions including: cancer, chronic inflammatory diseases, transplantation, infectious diseases and cardiovascular diseases [3] .

    Search related documents:
    Co phrase search for related documents